Abstract
This study collected and analyzed clinical data of psoriasis patients to develop and validate a psoriasis relapse risk prediction model. It aims to support early relapse risk assessment in clinical practice and inform the design of preventive interventions. To develop and validate a risk prediction model for psoriasis relapse. A convenience sampling method was used to select 504 psoriasis patients admitted to a tertiary hospital in China between January 2022 and December 2024, including 353 cases in the training set and 151 cases in the testing set. Independent risk factors for psoriasis relapse were identified through univariate analysis and logistic regression analysis to develop a prediction model. A nomogram and SHAP summary plot were generated for model visualization, and the model’s goodness of fit and discriminative ability were evaluated. The 1-year relapse rate of psoriasis patients after treatment was 66.67%. Logistic regression identified six independent risk factors for psoriasis relapse: BMI, diabetes, biologic use, smoking, upper respiratory tract infection (URTI), and non-standard medication, all of which were incorporated into the model. The area under the ROC curve (AUC) values for the training and testing sets were 0.767 [95% CI 0.715–0.818] and 0.704 [95% CI 0.620–0.789], respectively. The model showed moderate discrimination and good calibration. Decision curve analysis (DCA) confirmed clinically meaningful net benefit in both training and test sets. The predictive model for psoriasis relapse risk established in this study demonstrated only moderate predictive performance. This model can serve as a preliminary exploratory tool, providing a certain degree of quantitative reference for assessing the risk of psoriasis relapse; however, rigorous external validation in independent multicenter cohorts is still required before clinical application.
Similar content being viewed by others
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Boehncke, W.-H. & Schön, M. P. Psoriasis. Lancet 386, 983–994 (2015).
Dubertret, L. et al. European patient perspectives on the impact of psoriasis: The EUROPSO patient membership survey. Br. J. Dermatol. 155, 729–736 (2006).
Peng, C. et al. Epidemiological variations in the global burden of psoriasis, an analysis with trends from 1990 to 2017. Front. Med. 8, 585634 (2021).
Takeshita, J. et al. Psoriasis and comorbid diseases: Epidemiology. J. Am. Acad. Dermatol. 76, 377–390 (2017).
World Health Organization. Global Report on Psoriasis. (2016).
Skayem, C., Taieb, C., Halioua, B., Baissac, C. & Saint Aroman, M. Epidemiology of psoriasis: A worldwide global study. Acta Derm Venereol 105, adv42945 (2025).
Bu, J., Ding, R., Zhou, L., Chen, X. & Shen, E. Epidemiology of psoriasis and comorbid diseases: A narrative review. Front. Immunol. 13, 880201 (2022).
Cadrin-Tourigny, J. et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur. Heart J. 43, e1–e9 (2022).
Huang, S., Bai, Y., Qi, R., Yu, H. & Duan, X. Personalized prediction of psoriasis relapse post-biologic discontinuation: A machine learning-driven population cohort study. J. Dermatolog. Treat. 36, 2480743 (2025).
Huang, S., Chen, B., Qi, Y., Duan, X. & Bai, Y. Development and external validation of a prediction model for the risk of relapse in psoriasis after discontinuation of biologics. Front. Med. 11, 1488096 (2024).
Girolomoni, G. et al. Increasing access to effective systemic treatments in patients with moderate-to-severe psoriasis: Narrative review. Dermatol. Ther. 13, 2171–2185 (2023).
Wan, V. et al. Disparities and barriers to the access of biologics in moderate-to-severe adult psoriasis. Int. J. Dermatol. 63, 1293–1301 (2024).
Collins, G. S., Reitsma, J. B., Altman, D. G. & Moons, K. G. M. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. BMJ 350, g7594 (2015).
Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2023 edition). Chin. J. Dermatol. 56, 573–625 (2023).
Riley, R. D. et al. Calculating the sample size required for developing a clinical prediction model. BMJ 368, m441 (2020).
Huang, Y.-W. & Tsai, T.-F. Remission duration and long-term outcomes in patients with moderate-to-severe psoriasis treated by biologics or tofacitinib in controlled clinical trials: A 15-year single-center experience. Dermatol. Ther. 9, 553–569 (2019).
Francis, L., Capon, F., Smith, C. H., Haniffa, M. & Mahil, S. K. Inflammatory memory in psoriasis: From remission to relapse. J. Allergy Clin. Immunol. 154, 42–50 (2024).
Lee, E. B., Wu, K. K., Lee, M. P., Bhutani, T. & Wu, J. J. Psoriasis risk factors and triggers. Cutis 102, 18–20 (2018).
Zhang, L.-J. et al. Antimicrobial peptide LL37 and MAVS signaling drive interferon-β production by epidermal keratinocytes during skin injury. Immunity 45, 119–130 (2016).
Liu, S. et al. Triggers for the onset and relapse of psoriasis: a review and update. Cell Commun. Signal 22, 108 (2024).
Stewart, T. J., Tong, W. & Whitfeld, M. J. The associations between psychological stress and psoriasis: A systematic review. Int. J. Dermatol. 57, 1275–1282 (2018).
Potestio, L. et al. Risk factors for psoriasis flares: A narrative review. Psoriasis (Auckl) 14, 39–50 (2024).
Yang, H., Li, X., Zhang, L., Xue, F. & Zheng, J. Immunomodulatory effects of sleep deprivation at different timing of psoriasiform process on skin inflammation. Biochem. Biophys. Res. Commun. 513, 452–459 (2019).
Thorleifsdottir, R. H. et al. Throat Infections are associated with exacerbation in a substantial proportion of patients with chronic plaque psoriasis. Acta Derm. Venereol. 96, 788–791 (2016).
Johnston, A., Gudjonsson, J. E., Sigmundsdottir, H., Love, T. J. & Valdimarsson, H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin. Exp. Immunol. 138, 83–93 (2004).
Travers, J. B. et al. Epidermal HLA-DR and the enhancement of cutaneous reactivity to superantigenic toxins in psoriasis. J. Clin. Investig. 104, 1181–1189 (1999).
Chiricozzi, A., Gisondi, P., Bellinato, F. & Girolomoni, G. Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines https://doi.org/10.3390/vaccines8040769 (2020).
Shen, F. et al. Tobacco smoking was positively associated with disease relapse at week 24 and 48 among patients with psoriasis vulgaris in Shanghai: A prospective study. Psoriasis (Auckl) 15, 261–272 (2025).
Lee, E. J., Han, K. D., Han, J. H. & Lee, J. H. Smoking and risk of psoriasis: A nationwide cohort study. J. Am. Acad. Dermatol. 77, 573–575 (2017).
Armstrong, A. W., Armstrong, E. J., Fuller, E. N., Sockolov, M. E. & Voyles, S. V. Smoking and pathogenesis of psoriasis: A review of oxidative, inflammatory and genetic mechanisms. Br. J. Dermatol. 165, 1162–1168 (2011).
Carey, W. et al. Relapse, rebound, and psoriasis adverse events: An advisory group report. J. Am. Acad. Dermatol. 54, S171-181 (2006).
Svendsen, M. T. et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: A randomized controlled trial. Br. J. Dermatol. 179, 1062–1071 (2018).
Armstrong, A. W., Harskamp, C. T. & Armstrong, E. J. Psoriasis and the risk of diabetes mellitus: A systematic review and meta-analysis. JAMA Dermatol. 149, 84–91 (2013).
De Luca, D. A., Papara, C., Hawro, T. & Thaçi, D. Psoriasis and diabetes: A review of the pathophysiological and therapeutic interconnections. Minerva Med. 116, 195–222 (2025).
World Health Organization. Obesity and overweight. https://www.who.int/news-room/fa-ct-sheets/detail/obesity-and-overweight (2025).
Musumeci, M. L., Nasca, M. R., Boscaglia, S. & Micali, G. The role of lifestyle and nutrition in psoriasis: Current status of knowledge and interventions. Dermatol. Ther. 35, e15685 (2022).
Kunz, M., Simon, J. C. & Saalbach, A. Psoriasis: Obesity and fatty acids. Front. Immunol. 10, 1807 (2019).
Huang, Y.-H. et al. Predicting the time to relapse following withdrawal from different biologics in patients with psoriasis who responded to therapy: A 12-year multicenter cohort study. Am. J. Clin. Dermatol. 25, 997–1008 (2024).
Sun, X. et al. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. Autoimmun. Rev. 23, 103530 (2024).
Funding
This study was supported by the 2025 Hunan Provincial Natural Science Foundation Project (2025JJ80911).
Author information
Authors and Affiliations
Contributions
XZ: Conceptualization, Methodology, Investigation, Data curation, Writing—original draft. CZ: Investigation, Data curation, Writing Original Draft. YL: Coordination, Formal analysis, Project administration, Writing—review and editing. HH: Coordination, Project administration, Writing—review and editing. JG: Project administration, Writing—review and editing. XT: Project administration, Writing—review and editing. GJ: Funding acquisition, Project administration, Writing—review and editing. All the authors have read and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
About this article
Cite this article
Zhang, X., Zhao, C., Luo, Y. et al. Development and validation of a prediction model for the risk of relapse in psoriasis. Sci Rep (2026). https://doi.org/10.1038/s41598-026-47802-1
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-026-47802-1
